BCLI•benzinga•
BrainStorm Cell Therapeutics Submits IND Amendment to FDA for Phase 3b Trial of NurOwn in Amyotrophic Lateral Sclerosis
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 10, 2025 by benzinga